Team:USTC CHINA/Project/Overview
From 2013.igem.org
(Difference between revisions)
Line 68: | Line 68: | ||
</div> | </div> | ||
<div id="aim-bar" class="bassic-bar"> | <div id="aim-bar" class="bassic-bar"> | ||
- | <h1> | + | <h1>Project contains</h1> |
<p>For in situ transdermal vaccine is real a giant project, we devide it into four lab parts. And we expect to achieve following goals.</p> | <p>For in situ transdermal vaccine is real a giant project, we devide it into four lab parts. And we expect to achieve following goals.</p> | ||
<div id="aim-bar-col"> | <div id="aim-bar-col"> | ||
<h2>Antigen</h2> | <h2>Antigen</h2> | ||
+ | <div class="img-left-side"> | ||
+ | <img src="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_HBsAg.png" width="300" height="200"> | ||
+ | </div> | ||
<p>As the main part of T-vaccine, TD-1 is fused with antigen protein, so it can penetrate the skin and present antigen. We had designed there kinds of vaccine, which are against hepatitis B, TB and anthrax. Our ELISA test and mice test had proved their antigenicity and immunogenicity,thereby proving that T-vaccine can be generally used.</p></div> | <p>As the main part of T-vaccine, TD-1 is fused with antigen protein, so it can penetrate the skin and present antigen. We had designed there kinds of vaccine, which are against hepatitis B, TB and anthrax. Our ELISA test and mice test had proved their antigenicity and immunogenicity,thereby proving that T-vaccine can be generally used.</p></div> | ||
<div id="aim-bar-col"> | <div id="aim-bar-col"> |
Revision as of 10:00, 26 September 2013